Psychopharmacology and Psychiatry Updates Antipsychotics in Pregnancy: A Balancing Act
5 snips
Sep 23, 2024 Vivien Burt, Professor Emeritus of Psychiatry at UCLA, discusses the intricate decision-making process surrounding atypical antipsychotics use during pregnancy, particularly for women with bipolar disorder. She highlights recent research showing no significant risk of major birth defects, emphasizing the need to balance maternal mental health with fetal safety. The conversation stresses the importance of effective communication between healthcare providers and patients to navigate treatment benefits and potential risks for newborns.
AI Snips
Chapters
Transcript
Episode notes
Sarah's Pregnancy Medication Dilemma
- A 28-year-old pregnant woman named Sarah is managing bipolar disorder with olanzapine.
- She worries about birth defects if she continues medication but fears relapse if she stops.
Safety of Atypical Antipsychotics in Pregnancy
- Current data from large studies does not suggest atypical antipsychotics cause major birth defects.
- Use in pregnant women with serious psychiatric illness may be prudent despite some neonatal risks.
Placental Passage Varies Among Antipsychotics
- Olanzapine shows the highest placental passage compared to haloperidol, risperidone, and cotiapine.
- Despite this, choosing the most effective antipsychotic for the patient is recommended.